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Antibiotic resistance: inevitable?
When antibiotics first came into use, they
were so effective at curbing bacterial infec-
tions that it seemed the age-old battle of
man vs. microbe would soon be at an end
[1]. Eighty years and dozens of drugs
later, we now know better. Following each
new antibiotic’s launch, reports soon
accumulated that once-treatable infections
were becoming refractory to the drug [2].
Nowadays, many infectious strains are
already resistant to multiple antibiotics [3].
Treating such cases is becoming more
and more difficult, expensive and risky.
Meanwhile, the supply of new antibiotics
hasstalled.All thisaddsuptoamajorglobal
crisis. It is already underway, and it is
worsening every day [3].
The rise of resistance is simply adapta-
tion—evolution in action. Bacteria’s large
populations and their proclivity for
swapping genes mean that mutants arise
regularly, and thereafter, the fittest mutants
spread through natural selection. So is resi-
stance wholly inevitable? Not necessarily!
Evolutionary theory not only explains why
resistance occurs but it also offers clues as
to how we might be able to prevent it—or at
least slow it.
Evolutionary perspectives
First, we can try to reduce the risk of resist-
ance arising in the first place [4]. To resist a
single antibiotic, one mutation might suf-
fice, but to resist a ‘cocktail’ of distinct drug
types, more complex suites of mutations
may be needed—the odds of which should
be lower. We can also narrow the range of
potential ‘routes to resistance’. In bacteria,
resistance most typically involves changes
on or within cells - blocking a drug’s entry,
expelling or degrading it before it can act, or
altering its intracellular target [5]. Drugs
that act outside the cell may thus be less
likely to elicit resistance-conferring muta-
tions [6].
However, resistance can still arise, so we
should try to minimise its spread [4]. One
approach is to use drugs that curb bacterial
virulence but not growth. Mutants resistant
against such drugs, if they arise, should
have no growth advantage over susceptible
types. Another approach would be to target
the secreted virulence factors that are
shared cooperatively among co-infecting
bacteria. Mutants able to maintain produc-
tion of the shared virulence factors would
benefit both resistant and susceptible vari-
ants alike, and so should have no selective
advantage [4, 6].
Future implications
Dothese ideas for ‘evolution-proofing’have
empirical support? Combination therapy
has been used for years, yet data suggests
thatonlycertaindrugmixeswork—andonly
for certain infections [7]. More recent ideas,
however, may hold greater promise.
Examples include: (i) preventing adhesion
to host tissue [8]—a therapy that acts
extracellularly; (ii) inhibiting communica-
tion among bacteria [9]—a therapy inhibit-
ing the collective release of sharable toxins;
and (iii) the extracellular quenching of iron-
binding molecules [6]—another therapy
that, by targeting a social trait, curbs the
growthof resistantandsusceptiblebacteria
alike. ‘Evolution-proof’ therapies may thus
already exist, but more work is needed—
urgently—if they are to make their way into
the clinic.
references
1. Burnet M. Natural History of Infectious Disease,
1962. Cambridge University Press.
2. Clatworthy AE, Pierson E and Hung DT.
Targeting virulence: a new paradigm for
antimicrobial therapy. Nat Chem Biol 2007;3:
541–8.
3. WHO.AntimicrobialResistance:GlobalReporton
Surveillance, 2014.
4. Allen RC, Popat R, Diggle SP et al. Targeting
virulence: can we make evolution-proof drugs?
Nat Rev Microbiol 2014;12:300–8.
5. Ferna´ndez L and Hancock REW. Adaptive and
mutational resistance: role of porins and efflux
pumps in drug resistance. Clin Microbiol Rev
2012;25:661–81.
6. Ross-Gillespie A, Weigert M, Brown SP et al.
Gallium-mediated siderophore quenching as
an evolutionarily robust antibacterial treat-
ment. Evol Med Pub Health 2014;2:18–29.
7. Tamma PD, Cosgrove SE, Maragakis LL et al.
Combination therapy for treatment of infec-
tions with gram-negative bacteria. Clin Rev
Microbiol 2012;25:450–70.
emph clinical briefs
 The Author(s) 2014. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
 at Zentralbibliothek on February 5, 2015
http://em
ph.oxfordjournals.org/
D
ow
nloaded from
 
8. Travier L, Rendueles O, Ferrie´res L et al.
Escherichia coli resistance to nonbiocidal
antibiofilm polysaccharides is rare and med-
iated by multiple mutations leading to
surface physicochemical modifications. Anti-
microb Agents Chemother 2013;57:3960–68.
9. Lu C, Maurer CK, Kirsch B et al. Overcoming
the unexpected functional inversion of a PqsR
antagonist in Pseudomonas aeruginosa: an in
vivo potent antivirulence agent targeting pqs
quorum sensing. Angew Chem Int Ed 2014;53:
1109–12.
‘Evolution-Proofing’ Antibacterials Ross-Gillespie and Ku¨mmerli | 135
 at Zentralbibliothek on February 5, 2015
http://em
ph.oxfordjournals.org/
D
ow
nloaded from
 
